{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:11:38Z","timestamp":1770739898147,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,7,26]],"date-time":"2013-07-26T00:00:00Z","timestamp":1374796800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s11926-013-0355-x","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T11:52:27Z","timestamp":1374753147000},"source":"Crossref","is-referenced-by-count":7,"title":["Ocular Vasculitis"],"prefix":"10.1007","volume":"15","author":[{"given":"Gabriela M.","family":"Espinoza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levent","family":"Akduman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,26]]},"reference":[{"key":"355_CR1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","volume":"80","author":"A Rothova","year":"1996","unstructured":"Rothova A, Suttorp-van Schulten MSA, Treffers WF, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332\u20136.","journal-title":"Br J Ophthalmol"},{"key":"355_CR2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.27763","volume":"63","author":"JU Holle","year":"2011","unstructured":"\u2022\u2022 Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener\u2019s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011;63:257\u201366. A comparative study showing improved outcomes with the advent of improved therapeutic procedures.","journal-title":"Arthritis Rheum"},{"key":"355_CR3","first-page":"66","volume":"9","author":"GD Zlatanovic","year":"2012","unstructured":"\u2022 Zlatanovic GD, Jovanovic SV, Zivkovic MLJ, et al. The efficacy of novel therapeutic modalities of isolated ocular vasculitis vs ocular vasculitis as a systemic disease. Med Glas Ljek Komore Zenicko-doboj Kantona. 2012;9:66\u201373. This study brings to light the overall morbidity still associated with vasculitic diseases.","journal-title":"Med Glas Ljek Komore Zenicko-doboj Kantona"},{"key":"355_CR4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jpeds.2011.07.051","volume":"160","author":"I Pagnini","year":"2012","unstructured":"Pagnini I, Zannin ME, Vittadello F, et al. Clinical features and outcome of Cogan syndrome. J Pediatr. 2012;160:303\u20137.","journal-title":"J Pediatr"},{"key":"355_CR5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/ICU.0b013e32834bdfe2","volume":"22","author":"J Schmidt","year":"2011","unstructured":"\u2022\u2022 Schmidt J, Pulido JS, Matteson EL. Ocular manifestations of systemic disease: antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Ophthalmol. 2011;22:489\u201395. A thorough and important review of ANCA-associated vasculitides.","journal-title":"Curr Opin Ophthalmol"},{"key":"355_CR6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/01.ico.0000227886.26747.a9","volume":"25","author":"EN Yu","year":"2006","unstructured":"Yu EN, Jurkunas U, Rubin PA, et al. Obliterative microangiopathy presenting as chronic conjunctivitis in a patient with relapsing polychondritis. Cornea. 2006;25:621\u20132.","journal-title":"Cornea"},{"key":"355_CR7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1726-4901(09)70311-9","volume":"69","author":"YM Chung","year":"2006","unstructured":"Chung YM, Lin YC, Huang DF, et al. Conjunctival biopsy in sarcoidosis. J Chin Med Assoc. 2006;69:472\u20137.","journal-title":"J Chin Med Assoc"},{"key":"355_CR8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ophtha.2011.07.013","volume":"119","author":"M Sainz de la Maza","year":"2012","unstructured":"Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, et al. Clinical characteristics of a large cohort of patients with scleritis and Episcleritis. Ophthalmology. 2012;119:43\u201350.","journal-title":"Ophthalmology"},{"key":"355_CR9","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.ophtha.2012.05.013","volume":"119","author":"MS Katz","year":"2012","unstructured":"Katz MS, Chuck RS, Gritz DC. Scleritis and episcleritis. Ophthalmology. 2012;119:1715.","journal-title":"Ophthalmology"},{"key":"355_CR10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11926-003-0037-1","volume":"5","author":"JB Shepherd III","year":"2003","unstructured":"Shepherd III JB. Ocular vasculitis. Curr Rheumatol Rep. 2003;5:100\u20136.","journal-title":"Curr Rheumatol Rep"},{"key":"355_CR11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2012.07.052","volume":"120","author":"AC Gregory 2nd","year":"2013","unstructured":"\u2022 Gregory 2nd AC, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with Uveitis associated with juvenile idiopathic arthritis: the systemic immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120:186\u201392. A study of 327 patients with 596 affected eyes that delves into the causes of vision loss.","journal-title":"Ophthalmology"},{"key":"355_CR12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/08820530500232035","volume":"20","author":"AA Bonfioli","year":"2005","unstructured":"Bonfioli AA, Damico FM, Curi AL, et al. Intermediate uveitis. Semin Ophthalmol. 2005;20:147\u201354.","journal-title":"Semin Ophthalmol"},{"key":"355_CR13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.bor.0000149083.16639.7e","volume":"17","author":"CP Herbort","year":"2005","unstructured":"Herbort CP, Cimino L, AbuElAsrar AM. Ocular vasculitis: a multidisciplinary approach. Curr Opin Rheumatol. 2005;17:25\u201333.","journal-title":"Curr Opin Rheumatol"},{"key":"355_CR14","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1097\/IAE.0b013e3182618d43","volume":"32","author":"CP Herbort","year":"2012","unstructured":"Herbort CP, Neri P, El Asrar AA, et al. Is ICGA still relevant in inflammatory eye disorders? Why this question has to be dealt with separately from other eye conditions. Retina. 2012;32:1701\u20133.","journal-title":"Retina"},{"key":"355_CR15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10067-012-2078-1","volume":"32","author":"S Androudi","year":"2013","unstructured":"\u2022 Androudi S, Dastiridou A, Symeonidis C, et al. Retinal vasculitis in rheumatic disease: an unseen burden. Clin Rheumatol. 2013;32:7\u201313. A good review of retinal vasculitis with detailed ocular findings.","journal-title":"Clin Rheumatol"},{"key":"355_CR16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11926-010-0128-8","volume":"12","author":"G Espinoza","year":"2010","unstructured":"Espinoza G. Orbital inflammatory pseudotumors: etiology, differential diagnosis, and management. Curr Rheumatol Rep. 2010;12:443\u20137.","journal-title":"Curr Rheumatol Rep"},{"key":"355_CR17","first-page":"1025","volume":"28","author":"SL Harper","year":"2001","unstructured":"Harper SL, Letko E, Samson CM, et al. Wegener\u2019s Granulomatosis: the relationship between ocular and systemic disease. J Rheumatol. 2001;28:1025\u201332.","journal-title":"J Rheumatol"},{"key":"355_CR18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0161-6420(83)34574-7","volume":"90","author":"CL Bullen","year":"1983","unstructured":"Bullen CL, Liesegang TJ, McDonald TJ, et al. Ocular complications of Wegener\u2019s granulomatosis. Ophthalmology. 1983;90:279\u201390.","journal-title":"Ophthalmology"},{"key":"355_CR19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488\u201398.","journal-title":"Ann Intern Med"},{"key":"355_CR20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","volume":"33","author":"RY Leavitt","year":"1990","unstructured":"Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener\u2019s granulomatosis. Arthritis Rheum. 1990;33:1101\u20137.","journal-title":"Arthritis Rheum"},{"key":"355_CR21","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1001\/archinte.1989.00390110055012","volume":"149","author":"JW Tervaert","year":"1989","unstructured":"Tervaert JW, van der Woude FJ, Fauci AS, et al. Association between active Wegener\u2019s granulomatosis and aticytoplasmic antibodies. Arch Intern Med. 1989;149:2461\u20135.","journal-title":"Arch Intern Med"},{"key":"355_CR22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7326\/0003-4819-111-1-28","volume":"111","author":"B Nolle","year":"1989","unstructured":"Nolle B, Specks U, Ludemann J, et al. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med. 1989;111:28\u201340.","journal-title":"Ann Intern Med"},{"key":"355_CR23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","volume":"71","author":"JU Holle","year":"2012","unstructured":"Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener\u2019s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71:327\u201333.","journal-title":"Ann Rheum Dis"},{"key":"355_CR24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial Research Group","year":"2005","unstructured":"Wegener\u2019s Granulomatosis Etanercept Trial Research Group. Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N Engl J Med. 2005;352:351\u201361.","journal-title":"N Engl J Med"},{"key":"355_CR25","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ajo.2005.05.025","volume":"140","author":"M Fujita","year":"2005","unstructured":"Fujita M, Igarachi T, Kurai T, et al. Correlation between dry eye and rheumatoid arthritis activity. Am J Ophthalmol. 2005;140:808\u201313.","journal-title":"Am J Ophthalmol"},{"key":"355_CR26","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.rdc.2007.08.002","volume":"33","author":"A Galor","year":"2007","unstructured":"Galor A, Thorne JE. Scleritis and peripheral ulcerative keratitis. Rheum Dis Clin North Am. 2007;33:835\u201354.","journal-title":"Rheum Dis Clin North Am"},{"key":"355_CR27","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0161-6420(84)34160-4","volume":"91","author":"CS Foster","year":"1984","unstructured":"Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis: effects of systemic immunosuppression. Ophthalmology. 1984;91:1253\u201363.","journal-title":"Ophthalmology"},{"key":"355_CR28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/03009742.2011.573503","volume":"40","author":"MC Kapetanovic","year":"2011","unstructured":"Kapetanovic MC, Lindqvist E, Geborek P, et al. Long-term mortality rate in rheumatoid arthritis patients with disease onset in the 1980s. Scand J Rheumatol. 2011;40:433\u20138.","journal-title":"Scand J Rheumatol"},{"key":"355_CR29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MD.0b013e318211bf28","volume":"90","author":"H Ideguchi","year":"2011","unstructured":"Ideguchi H, Suda A, Takeno M, et al. Behcet disease: evolution of clinical manifestations. Medicine. 2011;90:125\u201332.","journal-title":"Medicine"},{"key":"355_CR30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"I Kotter","year":"2003","unstructured":"Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423\u201331.","journal-title":"Br J Ophthalmol"},{"key":"355_CR31","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/RHU.0b013e31823a46ed","volume":"17","author":"AC Oliveira","year":"2011","unstructured":"Oliveira AC, Buosi AL, Dutra LA, et al. Behcet disease: clinical features and management in a Brazilian tertiary hospital. J Clin Rheumatol. 2011;17:416\u201320.","journal-title":"J Clin Rheumatol"},{"key":"355_CR32","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajo.2012.03.035","volume":"154","author":"N Markomichelakis","year":"2012","unstructured":"\u2022 Markomichelakis N, Delicha E, Masselos S, et al. Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet disease: a pilot study in 15 patients. Am J Ophthalmol. 2012;154:534\u2013541.e1. This study shows a novel use of infliximab with good results in Behcet\u2019s disease.","journal-title":"Am J Ophthalmol"},{"key":"355_CR33","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"EB Suhler","year":"2005","unstructured":"Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory Uveitis. Arch Ophthalmol. 2005;123:903\u201312.","journal-title":"Arch Ophthalmol"},{"key":"355_CR34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archopht.125.7.895","volume":"125","author":"L Sobrin","year":"2007","unstructured":"Sobrin L, Kim EC, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007;125:895\u2013900.","journal-title":"Arch Ophthalmol"},{"key":"355_CR35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","volume":"111","author":"CC Murphy","year":"2004","unstructured":"Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with Infliximab for refractory Uveitis and scleritis. Ophthalmology. 2004;111:352\u20136.","journal-title":"Ophthalmology"},{"key":"355_CR36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00041327-200106000-00011","volume":"21","author":"JC Nichols","year":"2001","unstructured":"Nichols JC, Ince A, Akduman L, et al. Interferon-alpha 2a treatment of Neuro-Behcet Disease. J Neuro-Ophthalmol. 2001;21:109\u201311.","journal-title":"J Neuro-Ophthalmol"},{"key":"355_CR37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","volume":"130","author":"DA Jabs","year":"2000","unstructured":"Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492\u2013513.","journal-title":"Am J Ophthalmol"},{"key":"355_CR38","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68:696\u2013701.","journal-title":"Ann Rheum Dis"},{"key":"355_CR39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","volume":"47","author":"P Tynjala","year":"2008","unstructured":"Tynjala P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology. 2008;47:339\u201344.","journal-title":"Rheumatology"},{"key":"355_CR40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bjophthalmol-2012-302292","volume":"97","author":"EB Suhler","year":"2013","unstructured":"\u2022 Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicenter, open-label, prospective trial. Br J Ophthalmol. 2013;97:481\u20136. Well designed prospective study on adalimumab by a group that also has studied infliximab. The study draws comparisons between the growing body of literature regarding these medicines in the treatment of uveitis.","journal-title":"Br J Ophthalmol"},{"key":"355_CR41","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/bjophthalmol-2011-301401","volume":"97","author":"BC Dobner","year":"2013","unstructured":"Dobner BC, Max R, Becker MD, et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97:134\u20138.","journal-title":"Br J Ophthalmol"},{"key":"355_CR42","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2009.12.011","volume":"117","author":"S Androudi","year":"2010","unstructured":"Androudi S, Tsironi E, Kalogeropoulos C, et al. Intravitreal Adalimumab for refractory uveitis-related macular edema. Ophthalmology. 2010;117:1612\u20136.","journal-title":"Ophthalmology"},{"key":"355_CR43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semarthrit.2011.12.006","volume":"42","author":"A Sellas","year":"2012","unstructured":"\u2022 Sellas A, Rodriguez B, Barcelo M, et al. Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. Semin Arthritis Rheum. 2012;42:89\u2013103. An extensive review of the use of TNF antagonists and their role in the treatment of sarcoidosis.","journal-title":"Semin Arthritis Rheum"},{"key":"355_CR44","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088\u201394.","journal-title":"Gastroenterology"},{"key":"355_CR45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11926-012-0290-2","volume":"14","author":"F Silva","year":"2012","unstructured":"Silva F, Cisternas M, Specks U. TNF-alpha Blocker Therapy and Solid Malignancy Risk in ANCA-Associated Vasculitis. Curr Rheumatol Rep. 2012;14:501\u20138.","journal-title":"Curr Rheumatol Rep"},{"key":"355_CR46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"A Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E, et al. Anti-TNF agents for Behcet\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41:61\u201370.","journal-title":"Semin Arthritis Rheum"},{"key":"355_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0b013e3181cde727","volume":"30","author":"JS Pulido","year":"2010","unstructured":"\u2022 Pulido JS, Pulido JE, Michet CJ, et al. More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial. Retina. 2010;30:1\u20135. A thorough discussion of intravitreal biologics and ethical dilemmas of treatment in refractory cases of disease.","journal-title":"Retina"},{"key":"355_CR48","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/09273941003739928","volume":"18","author":"B Iaccheri","year":"2010","unstructured":"Iaccheri B, Androudi S, Bocci EB, et al. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm. 2010;18:223\u20135.","journal-title":"Ocul Immunol Inflamm"},{"key":"355_CR49","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/bjo.2008.147157","volume":"93","author":"S Chauhan","year":"2009","unstructured":"Chauhan S, Kamal A, Thompson RN, et al. Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol. 2009;93:984\u20135.","journal-title":"Br J Ophthalmol"},{"key":"355_CR50","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med. 2010;363:221\u201332.","journal-title":"N Engl J Med"},{"key":"355_CR51","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/sj.eye.6702804","volume":"21","author":"AS Kitzmann","year":"2007","unstructured":"Kitzmann AS, Pulido JS, Mohney BG, et al. Intraocular use of rituximab. Eye. 2007;21:1524\u20137.","journal-title":"Eye"},{"key":"355_CR52","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/eye.2010.111","volume":"24","author":"S Yeh","year":"2010","unstructured":"Yeh S, Wilson DJ. Combination intravitreal rituximab and methotrexate for massive subretinal lymphoma. Eye. 2010;24:1625\u20137.","journal-title":"Eye"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-013-0355-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-013-0355-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-013-0355-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T08:06:07Z","timestamp":1563523567000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-013-0355-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,26]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["355"],"URL":"https:\/\/doi.org\/10.1007\/s11926-013-0355-x","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,26]]},"article-number":"355"}}